New York State Common Retirement Fund Acquires 156,086 Shares of CorMedix Inc. (NASDAQ:CRMD)

New York State Common Retirement Fund increased its holdings in shares of CorMedix Inc. (NASDAQ:CRMD - Free Report) by 1,398.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,249 shares of the company's stock after acquiring an additional 156,086 shares during the period. New York State Common Retirement Fund owned approximately 0.28% of CorMedix worth $1,355,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in CRMD. FMR LLC grew its stake in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company's stock worth $37,000 after buying an additional 1,625 shares during the last quarter. AlphaMark Advisors LLC grew its stake in shares of CorMedix by 16.7% in the fourth quarter. AlphaMark Advisors LLC now owns 14,000 shares of the company's stock worth $113,000 after acquiring an additional 2,000 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of CorMedix by 10.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,184 shares of the company's stock valued at $422,000 after acquiring an additional 4,935 shares in the last quarter. Rhumbline Advisers raised its position in shares of CorMedix by 8.6% in the 4th quarter. Rhumbline Advisers now owns 75,747 shares of the company's stock worth $614,000 after purchasing an additional 6,028 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in shares of CorMedix by 130.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,950 shares of the company's stock worth $97,000 after purchasing an additional 6,761 shares during the last quarter. Institutional investors own 34.18% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CRMD has been the subject of a number of analyst reports. D. Boral Capital restated a "buy" rating and set a $15.00 price objective on shares of CorMedix in a research note on Wednesday. StockNews.com raised shares of CorMedix to a "sell" rating in a research report on Friday, November 8th. Finally, Royal Bank of Canada increased their target price on CorMedix from $11.00 to $12.00 and gave the company an "outperform" rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

CorMedix Price Performance

CorMedix stock traded down $0.31 during midday trading on Thursday, reaching $9.80. 175,790 shares of the company traded hands, compared to its average volume of 1,072,433. CorMedix Inc. has a 12 month low of $3.03 and a 12 month high of $13.85. The firm has a market capitalization of $594.63 million, a price-to-earnings ratio of -12.11 and a beta of 1.57. The business has a 50 day moving average of $10.47 and a two-hundred day moving average of $9.44.

CorMedix Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.